CA1179328A - Oxytocin analogs and method for preparation thereof - Google Patents
Oxytocin analogs and method for preparation thereofInfo
- Publication number
- CA1179328A CA1179328A CA000380428A CA380428A CA1179328A CA 1179328 A CA1179328 A CA 1179328A CA 000380428 A CA000380428 A CA 000380428A CA 380428 A CA380428 A CA 380428A CA 1179328 A CA1179328 A CA 1179328A
- Authority
- CA
- Canada
- Prior art keywords
- oxytocin
- series
- amino acids
- group
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title abstract description 14
- 150000001413 amino acids Chemical class 0.000 claims abstract description 24
- MRNKEVGKBFIFET-AHCPCVRLSA-N (2s)-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-1-[(4s,7s,10s,16s)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2s)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1-thia-5,8,11,14,17-pentazacycloicosane-4-carb Chemical compound C([C@H]1C(=O)NC(C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 MRNKEVGKBFIFET-AHCPCVRLSA-N 0.000 claims abstract description 23
- 108700042417 deamino-6-carba- oxytocin Proteins 0.000 claims abstract description 23
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 23
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract description 22
- -1 ethoxy, amino, substituted amino Chemical group 0.000 claims abstract description 14
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
- 150000002148 esters Chemical class 0.000 claims abstract description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 34
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- ACNKIIZVPGLXMP-YFKPBYRVSA-N (2S)-4-carboxysulfanyl-2-(ethylamino)butanoic acid Chemical group C(=O)(O)SCC[C@H](NCC)C(=O)O ACNKIIZVPGLXMP-YFKPBYRVSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 4
- 229960001723 oxytocin Drugs 0.000 abstract description 13
- 101800000989 Oxytocin Proteins 0.000 abstract description 10
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 abstract description 10
- 230000003213 activating effect Effects 0.000 abstract description 4
- QBETWIZYARXLPZ-YFKPBYRVSA-N (2s)-2-amino-4-(2-carboxyethylsulfanyl)butanoic acid Chemical group OC(=O)[C@@H](N)CCSCCC(O)=O QBETWIZYARXLPZ-YFKPBYRVSA-N 0.000 abstract 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 abstract 1
- 238000010511 deprotection reaction Methods 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- 239000000047 product Substances 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 229960005190 phenylalanine Drugs 0.000 description 10
- 235000008729 phenylalanine Nutrition 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 102400000050 Oxytocin Human genes 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000004108 freeze drying Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 238000002523 gelfiltration Methods 0.000 description 5
- 230000001452 natriuretic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000037230 mobility Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- BTANRVKWQNVYAZ-SCSAIBSYSA-N (2R)-butan-2-ol Chemical compound CC[C@@H](C)O BTANRVKWQNVYAZ-SCSAIBSYSA-N 0.000 description 1
- AWKDBHFQJATNBQ-JTQLQIEISA-N (2s)-2-azaniumyl-3-(4-ethylphenyl)propanoate Chemical compound CCC1=CC=C(C[C@H](N)C(O)=O)C=C1 AWKDBHFQJATNBQ-JTQLQIEISA-N 0.000 description 1
- LVYWYLGWSVIFEV-ZDUSSCGKSA-N (2s)-3-(2-nitrophenyl)-2-(phenylsulfanylamino)propanoic acid Chemical compound C([C@@H](C(=O)O)NSC=1C=CC=CC=1)C1=CC=CC=C1[N+]([O-])=O LVYWYLGWSVIFEV-ZDUSSCGKSA-N 0.000 description 1
- LHJGJYXLEPZJPM-UHFFFAOYSA-N 2,4,5-trichlorophenol Chemical compound OC1=CC(Cl)=C(Cl)C=C1Cl LHJGJYXLEPZJPM-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 239000003160 antidiuretic agent Substances 0.000 description 1
- 229940124538 antidiuretic agent Drugs 0.000 description 1
- GRDMQWRBLJZFML-UHFFFAOYSA-N bis(4-nitrophenyl) sulfite Chemical compound C1=CC([N+](=O)[O-])=CC=C1OS(=O)OC1=CC=C([N+]([O-])=O)C=C1 GRDMQWRBLJZFML-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000002196 ecbolic effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 1
- 238000001997 free-flow electrophoresis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000013080 microcrystalline material Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000000709 neurohypophysis hormone Substances 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 238000007344 nucleophilic reaction Methods 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- GAPYKZAARZMMGP-UHFFFAOYSA-N pyridin-1-ium;acetate Chemical compound CC(O)=O.C1=CC=NC=C1 GAPYKZAARZMMGP-UHFFFAOYSA-N 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS4465-80 | 1980-06-24 | ||
| CS804465A CS216722B1 (en) | 1980-06-24 | 1980-06-24 | Oxytocine analogues and method of making the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1179328A true CA1179328A (en) | 1984-12-11 |
Family
ID=5387463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000380428A Expired CA1179328A (en) | 1980-06-24 | 1981-06-23 | Oxytocin analogs and method for preparation thereof |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS5753448A (en, 2012) |
| CA (1) | CA1179328A (en, 2012) |
| CH (1) | CH649090A5 (en, 2012) |
| CS (1) | CS216722B1 (en, 2012) |
| DE (1) | DE3124818A1 (en, 2012) |
| FR (1) | FR2485527B1 (en, 2012) |
| GB (1) | GB2078755B (en, 2012) |
| IT (1) | IT1136670B (en, 2012) |
| SE (1) | SE448303B (en, 2012) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI463990B (zh) * | 2009-09-21 | 2014-12-11 | Ferring Bv | 催產素受體促進劑 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2121052B (en) * | 1982-05-10 | 1985-08-14 | Ceskoslovenska Akademie Ved | Analogues of neurohypophysial hormones with inhibitory properties |
| JPS60198113A (ja) * | 1984-03-21 | 1985-10-07 | 松下電器産業株式会社 | 柑橘類の果汁絞り器 |
| JPS60166706U (ja) * | 1984-04-13 | 1985-11-06 | ナショナル住宅産業株式会社 | 外壁パネルの固定構造 |
| ZA87275B (en) * | 1986-01-16 | 1988-08-31 | Smithkline Beckman Corp | Polypeptide compounds |
| AT398767B (de) * | 1988-05-26 | 1995-01-25 | Gebro Broschek Gmbh | Verfahren zur reinigung eines rohpeptids mittels präparativer mitteldruckflüssigkeitschromatographie |
| US5225528A (en) * | 1990-02-27 | 1993-07-06 | Merck & Co., Inc. | Cyclic hexapeptide oxytocin antagonists |
| RU2125062C1 (ru) * | 1997-04-10 | 1999-01-20 | Государственный научный центр вирусологии и биотехнологии "Вектор" | Защищенные производные окситоцина |
| CN111454333B (zh) * | 2019-01-22 | 2023-06-27 | 南京济群医药科技股份有限公司 | 一种高纯度缩宫素的制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS194980B1 (en) * | 1976-07-16 | 1979-12-31 | Joseph H Cort | Agent for current induction,fertilization facilitating and milkability increasing at mammals,especially at utility cattle |
-
1980
- 1980-06-24 CS CS804465A patent/CS216722B1/cs unknown
-
1981
- 1981-06-16 SE SE8103778A patent/SE448303B/sv not_active IP Right Cessation
- 1981-06-17 IT IT22390/81A patent/IT1136670B/it active
- 1981-06-18 GB GB8118815A patent/GB2078755B/en not_active Expired
- 1981-06-19 CH CH4086/81A patent/CH649090A5/de not_active IP Right Cessation
- 1981-06-23 CA CA000380428A patent/CA1179328A/en not_active Expired
- 1981-06-23 FR FR8112293A patent/FR2485527B1/fr not_active Expired
- 1981-06-24 DE DE19813124818 patent/DE3124818A1/de not_active Withdrawn
- 1981-06-24 JP JP56098125A patent/JPS5753448A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI463990B (zh) * | 2009-09-21 | 2014-12-11 | Ferring Bv | 催產素受體促進劑 |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2078755B (en) | 1984-01-18 |
| FR2485527B1 (fr) | 1985-08-02 |
| JPS5753448A (en) | 1982-03-30 |
| CH649090A5 (de) | 1985-04-30 |
| FR2485527A1 (fr) | 1981-12-31 |
| IT8122390A0 (it) | 1981-06-17 |
| JPS6330318B2 (en, 2012) | 1988-06-17 |
| GB2078755A (en) | 1982-01-13 |
| DE3124818A1 (de) | 1982-04-08 |
| SE8103778L (sv) | 1981-12-25 |
| SE448303B (sv) | 1987-02-09 |
| CS216722B1 (en) | 1982-11-26 |
| IT1136670B (it) | 1986-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0355572B1 (de) | Peptidderivate, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| CA1179328A (en) | Oxytocin analogs and method for preparation thereof | |
| US3817973A (en) | Process for the preparation of cyclopeptides derived from polymyxins | |
| US3980631A (en) | Novel analogs of deamino-vasopressin with a modified disulfide bridge and manufacturing process thereof | |
| CA1176193A (en) | Peptide, process for their preparation and pharmaceutical composition containing them | |
| EP0309983A2 (de) | Enzymatisches Verfahren zur Herstellung von Peptiden, insbesondere Dipeptiden und Vorrichtung dafür | |
| JPS62277397A (ja) | 新規なペプチド | |
| US4482486A (en) | Analogs of vasopressin | |
| Rosenberg et al. | The isolation of lombricine and its possible biological precursor | |
| EP0292729A2 (de) | Neue Festphasen-Peptidsynthesemethoden | |
| SU1396970A3 (ru) | Способ получени производных гонадолиберина | |
| DE2463205C2 (de) | Octapeptid und Verfahren zu dessen Herstellung | |
| US4533494A (en) | Process for purifying secretin | |
| DE2831534C2 (de) | Octapeptide, Verfahren zu ihrer Herstellung und diese Octapeptide enthaltende Angiotensin-II-antagonistisch wirkende Arzneimittel | |
| US3973006A (en) | Peptide enzyme inhibitors of angiotensin I | |
| DE69736561T2 (de) | Acyltransfer mit einem stabilisierten übergangskomplex unter verwendung eines katalysators mit einer katalytischen imidazolfunktion (z.b. histidin) | |
| EP0354820B1 (en) | Novel peptide derivatives and anti-dementia agents | |
| CN103467593A (zh) | 一种胸腺法新的纯化方法 | |
| DE2342862C3 (de) | An beiden Kettenenden Reste von a -Aminooxycarbonsäuren aufweisende Peptide mit ACTH-Wirkung, Verfahren zu ihrer Herstellung und diese Peptide enthaltende Arzneimittel | |
| EP0227410A2 (en) | Peptide derivatives, their production and use | |
| Ravdel et al. | 6-Glycine-8-phenyllactic acid bradykinin. Its synthesis, biological activity, and splitting by kininase (carboxypeptidase N) | |
| US3960828A (en) | Catalytic hydrogenolysis of protected sulfur containing peptides | |
| Markussen et al. | Duck insulin: isolation, crystallization and amino acid sequence | |
| SU1341970A1 (ru) | Аналог энкефалина, обладающий анальгетической активностью | |
| Amoscato et al. | Synthesis and biological activity of [L-3, 4-dehydroproline3]-tuftsin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |